|
Back to Home » September 2022 News » ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival |
ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival |
September 09, 2022
While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease...
Source URL: https://www.prnewswire.com:443/news-releases/esmo-2022-interim-results-for-treatment-of-platinum-resistant-ovarian-cancer-with-p62-plasmid-dna-show-statistically-significant-changes-in-progression-free-survival-301620958.html
|
|
|
|
